Medical decisions in multiple system atrophy: a study in Austria
Part of Brain & nervous system clinical trials.
This study looks at how medical decisions are made for people with multiple system atrophy (MSA). It includes both people with MSA and their unpaid caregivers who live in Austria and speak German. Participants and caregivers will share their experiences through online interviews to help improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 30 years or older.
- You have been diagnosed with probable or established multiple system atrophy (MSA).
- Your doctor expects you to live at least 2 more years.
- You can give informed consent yourself (a legal representative cannot do it for you).
- You speak and read German fluently.
- If you cannot walk without help, you must live in Tyrol or another Austrian region with mobile palliative care.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new drug called ALT001 for people with multiple system atrophy (MSA). It aims to see if the drug is safe and may help slow the disease.
This study looks at how the body handles blood sugar (insulin resistance) in people with multiple system atrophy (MSA). Results may help doctors understand the disease better and explore new ways to monitor or treat it.
This trial tests a new antibody therapy that may target and remove abnormal proteins in the brain linked to Multiple System Atrophy (MSA). It aims to see if the treatment is safe and whether it can help slow the progression of the disease.
This study is collecting information from patients with multiple system atrophy (a rare neurological condition affecting movement and body functions), Parkinson disease, and healthy volunteers to better understand these conditions. By participating, you help doctors learn more about how these diseases develop and progress.
This study uses brain scans and clinical check-ins to better diagnose and predict how Parkinson-related conditions may progress over time. It may help researchers find markers that explain why symptoms change, and could improve future care.
This study collects data from people with Parkinson's disease or multiple system atrophy (MSA) to better understand these conditions. You will have blood, saliva, optional spinal fluid tests, and brain scans (MRI, PET/SPECT).
Hear when a new Multiple System Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.